The short answer is yes with meaningful caveats
Both medications help regulate appetite while supporting gradual, sustainable fat loss
It works on both the GIP and GLP-1 receptor pathways, which is why many patients group it with GLP-1 weight-loss injections
GLP-1 receptor agonists are a class of medications that mimic the action of glucagon-like peptide-1, an incretin hormone naturally produced in the intestinal L-cells following food intake
Con Premium Acceso a todos los documentos Descargas ilimitadas Herramientas IA (Flashcards, Quizzes y Practicar) Desbloquear documento Acceso solamente a este documento Descarga este documento Flashcards del documento Listo para repasar con flashcards instantneas
Graphical Abstract Similar content being viewed by others Introduction Non-alcoholic fatty liver disease (NAFLD) is considered to be the hepatic manifestation of the metabolic syndrome, which is believed to affect approximately 25% of adults worldwide and more than half of individuals with type 2 diabetes mellitus [1]
